Names
Pirtobrutinib Jaypirca®Indications and usage
Pirtobrutinib is indicated for the treatment of
- Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. - Adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent BTK inhibitor.
Side effects needing medical attention
Most common adverse reactions are fatigue, musculoskeletal pain, diarrhea, COVID-19, bruising, and cough. The most common laboratory abnormalities are neutrophil count decreased, platelet count decreased, hemoglobin decreased, and lymphocyte count decreased.